← Back to Search

N/A

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

N/A
Recruiting
Research Sponsored by Target PharmaSolutions, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection. The initial phase of the study that enrolled patients treated with tenofovir alafenamide (TAF) was successfully completed. The current protocol (Amendment 1) describes the second phase of the study that will engage research activities for patients being managed for CHB in usual clinical practice in the US and Canada. The study addresses important clinical questions regarding the management of CHB by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to antiviral treatments used in clinical practice.

Eligible Conditions
  • Hepatitis B
  • Hepatitis
  • Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: tenofovir alafenamideExperimental Treatment0 Interventions
Patients with a medication history of tenofovir alafenamide (TAF).

Find a Location

Who is running the clinical trial?

Target PharmaSolutions, Inc.Lead Sponsor
16 Previous Clinical Trials
5,661,582 Total Patients Enrolled
~698 spots leftby Jan 2026